Expanding the chemical and therapeutic landscape of 5H-Indeno[1,2-b]pyridin-5-one derivatives: Novel anticancer activity, EGFR inhibition, and modulation of HIF–VEGF and PI3K/AKT/mTOR pathways supported by computational insights

This publication has 73 references indexed in Scilit:

• Novel combination therapy of osimertinib and Tupichinol E in triple-negative breast cancer: Targeting EGFR and CDK4/6 pathways
  Aspects of Molecular Medicine, 2025
• Biochemical and molecular docking-based assessment of 's bioactive constituents for their potential application as natural anticancer drug
  Algal Research, 2024
• Tumor suppressor miR-218 directly targets epidermal growth factor receptor (EGFR) expression in triple-negative breast cancer, sensitizing cells to irradiation
  Journal of Cancer Research and Clinical Oncology, 2023
• Discovery of novel indene-based hybrids as breast cancer inhibitors targeting Hsp90: Synthesis, bio-evaluation and molecular docking study
  Arabian Journal of Chemistry, 2023
• Can EGFR be a therapeutic target in breast cancer?
  Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2022
• Innovation in cancer therapeutics and regulatory perspectives
  Medical Oncology, 2022
• Synthesis of 5H‐indeno[1,2‐b]pyridine derivatives: Antiproliferative and antimetastatic activities against two human prostate cancer cell lines
  Archiv der Pharmazie, 2021
• An overview of cancer multidrug resistance: a still unsolved problem
  Cellular and Molecular Life Sciences, 2008
• Application of the MTT assay to human prostate cancer cell lines in vitro: Establishment of test conditions and assessment of hormone‐stimulated growth and drug‐induced cytostatic and cytotoxic effects
  The Prostate, 1988
• Heterocyclic Tricycles as Potential CNS Agents I: 4-Aminoalkylindeno[1,2-c]pyrazoles
  Journal of Pharmaceutical Sciences, 1978